Take a look through some of the notable data presentations at this year's ESMO Congress.
Feature|Articles|May 30, 2025
ASCO 2025: What to watch for in GU oncology
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
This year's meeting with feature several notable sessions in prostate cancer, bladder cancer, kidney cancer, and other GU malignancies.
Advertisement
Advertisement
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is set to kick off on May 30, 2025 in Chicago, Illinois. Spanning 5 days, the conference will feature several notable sessions across prostate cancer, bladder cancer, kidney cancer, and other genitourinary malignancies. In this article, we highlight practice-shifting abstracts that urologists should keep an eye on during this year’s meeting.
Related to this article
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Advertisement
Advertisement